TRK fusion proteins are pathognomonic in certain rare tumour types and present in a small subset of diverse cancer types, including some common cancers; TRK inhibitors have promising efficacy in the treatment of these cancers, in a histology-agnostic manner. In this Review, the biology of TRK signalling and TRK fusions, strategies to target these drivers, the unique safety profile of TRK…
The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I…
Lung cancer is the leading cause of cancer-related death worldwide. The aim of the KBP-2020 study was to describe survival among patients diagnosed with lung…
PURPOSEThis study evaluated the efficacy and safety of avutometinib (rapidly accelerated fibrosarcoma/mitogen-activated extracellular signal-regulated kinase [MEK] clamp) alone or in combination with defactinib (focal adhesion…
In this episode of the IJGC podcast, Editor-in-Chief Dr. Pedro Ramirez is joined by Dr. Henri Azaïs to discuss ctDNA in Ovarian Cancer. Dr. Henri…
The incidence of early-onset gastrointestinal cancers—commonly defined as being diagnosed in patients <50 years of age—is rising at an alarming rate glo
wn to increase the risk of hepatocellular carcinoma (HCC), while vinyl chloride is a cause of angiosarcoma of the liver. A number of other environmental…
